

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and
Waiver under 21 U.S.C. 355(n)(4)

Michael Perry, M.D.

Committee: Oncologic Drugs Advisory Committee

Meeting Date: July 24, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to New Drug Application (NDA) 021,801, proposed trade name Orplatna (satraplatin capsules), originally developed by Johnson Matthey Pharmaceuticals, a subsidiary of Johnson Matthey PLC, with licensing rights to Spectrum Pharmaceuticals. Spectrum Pharmaceuticals licensed the global rights to GPC Biotech AG, proposed indication for the treatment of patients with androgen independent (hormone refractory) prostate cancer (HRPC) that has failed prior chemotherapy, I am eligible to receive a waiver under 21 U.S.C. 355 (n)(4).

Type of Interest	Nature	Magnitude
Stock	1 Competing firm	Less than \$5,001
Stock	2 Competing firms	Worth from \$5,001 to \$25,000 per firm

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

_____/S/_____
Signature of SGE

Date

June 7, 2007